Ruella, Marco http://orcid.org/0000-0003-4301-5811
Korell, Felix http://orcid.org/0000-0001-7699-7212
Porazzi, Patrizia
Maus, Marcela V. http://orcid.org/0000-0002-7578-0393
Article History
Accepted: 5 September 2023
First Online: 31 October 2023
Competing interests
: M.R. holds patents related to chimeric antigen receptor-T cells that are managed by the University of Pennsylvania, and some of them are licensed to Novartis, Tmunity and viTToria Biotherapeutics. M.R. has served as a consultant for BMS, GSK, Scailyte, Bayer, GLG and AbClon. M.R. receives research funding from viTToria Biotherapeutics, ONI, Beckman Coulter and AbClon. M.R. is the scientific founder of viTToria Biotherapeutics. M.V.M. is an inventor on patents related to chimeric antigen receptor-T cell therapies held by the University of Pennsylvania (some licensed to Novartis) and Massachusetts General Hospital (some licensed to Promab and Satellite Bio). M.V.M. holds equity in 2Seventy Bio, TCR2, Century Therapeutics, Oncternal and Neximmune, and has served as a consultant for multiple companies involved in cell therapies. M.V.M. serves on the Board of Directors of 2Seventy Bio. F.K. and P.P. declare no competing interests.